REFERENCES
- Hustu HO. Treatment of clinically localized Ewing's sar-coma with radiotherapy and combination chemotherapy. Cancer 1972; 30: 1522–1527.
- Johnson RE, Pomeroy TC. Integrated therapy for Ewing's sarcoma. Am J Roentgenol 1975; 123: 583–587.
- Jaffe N, Traggis D, Salian S et al. Improved outlook of Ewing's sarcoma with combination chemotherapy (vincristine, actinomycin D and cyclophosphamide) and radiation therapy. Cancer 1976; 38: 1925–1930.
- Rosen G, Caparros B, Mosende C, McCormick B, Huvos AG, Marcove RC. Curability of Ewing's sarcoma and considerations for future therapeutic trials. Cancer 1978; 41: 888–899.
- Bacci G, Campanacci M, Pagani PA. Adjuvant chemo-therapy in the treatment of clinically localised Ewing's sarcoma. J Bone Joint Surg 1978; 60: 567–574.
- Jurgens H, Exner U, Gadner H et al. Multidisciplinary treatment of primary Ewing's sarcoma of bone. Cancer 1988; 61: 23–32.
- Bacci G, Toni A, AveIla M et al. Long term results in 144 localized Ewing's sarcoma patients treated with combined therapy. Cancer 1989; 63: 1477–1486.
- Nesbit ME, Gehan EA, Burgert EO et al. Multimodal therapy for the management of primary nonmetastatic Ewing's sarcoma of bone: a long-term follow-up of the first intergroup study. J Clin Oncol 1990; 8: 1664–1674.
- Burgert EO, Nesbit ME, Garnsey LA et al. Multimodal therapy for the management of nonpelvic, localized Ewing's sarcoma of bone: intergroup study IESS-II. J Clin Oncol 1990; 8: 1514-1524.
- Oberlin O, Habrand JL, Zucker JM et al. No benefit of ifosfamide in Ewing's sarcoma: a nonrandomized study of the French Society of Pediatric Oncology. J Clin Oncol 1992; 10: 1407-1412.
- Craft AW, Cotterill SJ, Bullimore JA, Pearson D. Long-term results from the first UKCCSG Ewing's Tumour Study (ET-1). Eur J Cancer 1997; 61: 1061-1069.
- Bacci G, Picci P, Ruggieri P et al. No advantages in the addition of ifosfamide and VP-16 to the standard four-drug regimen in the maintenance phase of neoadjuvant chemo-therapy of Ewing's sarcoma of bone: results of two sequential studies. J Chemother 1993; 5: 247–257.
- Gobel V, Jurgens H, Etspuler G et al. Prognostic signif-icance of tumor volume in localized Ewing's sarcoma of bone in children and adolescents. J Cancer Res Clin Oncol 1987; 113: 187–191.
- Enneking WF, Spanier SS, Goodman MA. The surgical staging of muscoloskeletal sarcoma. J Bone Joint Surg (Am) 1980; 62: 1027–1030.
- Picci P, Rougraff BT, Bacci G et al. Prognostic signifi-cance of histopathologic response to chemotherapy in non-metastatic Ewing's sarcoma of the extremities. J Clin Oncol 1993; 11: 1763–1769.
- Magrath IT, Sandlund JT, Raynor A, et al. A phase II study of ifosfamide in the treatment of recurrent sarcomas in young people. Cancer Chemother Pharmacol 1986; 2: 525–528.
- Antman KH, Ryan L, Elias A et al. Response to ifos-famide and mesna in 124 previously treated patients with metastatic or unresectable sarcoma. J Clin Oncol 1987; 113: 187–191.
- Miser JS, Kinsella TJ, Triche TJ et al. Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of chil-dren and young adults. J Clin Oncol 1987; 5: 1191-1198.
- Kung FH, Pratt CB, Krisker J. Ifosfamide and VP-16 in the treatment of recurrent malignant solid tumors of child-hood. A phase II study. ASCO 1989 Abstract 1174.
- Dunst J, Jurgens H, Sauer R et al. Radiation therapy in Ewing's sarcoma: an update of the CESS 86 trial. Int J Radiat Oncol 1995; 4: 919–930.
- Craft AW, Cotterill SJ, Imeson J. Improvement in sur-vival for Ewing's sarcoma by substitution of ifosfamide for cyclophosphamide. A UKCCSG/MRC Study. Am J Pediat Haematol 1993; 15 (Suppl.A): 31-35.
- Bacci G, Picci P, Avella M, et al. Neoadjuvant chemo-therapy for localized Ewing's sarcoma of bone: experience at the Istituto Ortopedico Rizzoli. Cancer J 1991; 4: 335–342.
- Winkler K, Beron G, Delling G et al. Neoadjuvant chemotherapy of osteosarcoma: results of a randomized trial (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol 1988; 6: 329–337.
- Goldie JH, Coldman AJ. A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979; 63: 1727–1733.